X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IBC-Ab002 is a novel, fully human anti-PD-L1 monoclonal antibody designed to harness the peripheral immune system to rewire brain/immune communication and protect the brain from functional loss in the patients with alzheimer's disease.
Lead Product(s): IBC-Ab002
Therapeutic Area: Neurology Product Name: IBC-Ab002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Details:
The grant will be used to support the first-in-human clinical study of IBC-Ab002, a proprietary anti-PD-L1 antibody developed and engineered with differentiating characteristics tailored for the treatment of Alzheimer’s disease.
Lead Product(s): IBC-Ab002
Therapeutic Area: Neurology Product Name: IBC-Ab002
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: NIA
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Funding August 27, 2021
Details:
The grant will phase 1 clinical trial to examine safety and activity of its proprietary antibody, IBC-Ab002, targeted to enhance the immune system and induce brain repair processes in individuals with Alzheimer’s disease.
Lead Product(s): IBC-Ab002
Therapeutic Area: Neurology Product Name: IBC-Ab002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alzheimer’s Association
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Funding September 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
